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γ-Aminobutyric acid (GABA) is an inhibitory
neurotransmitter concerned with the control of neu-
ronal activity in the mammalian central nervous sys-
tem (CNS). There is considerable direct and indirect
evidence that impair activity of GABA-mediated
inhibitory synapses may be an important causative
factor in experimental and clinical seizure disorders
(1, 2). 
Enhancement of GABA transmission by inhi-
bition of GABA uptake has gained much attention
as a therapeutic strategy, since it functionally
increases the effect of GABA in a use-dependent
manner, and GABA uptake inhibition has proved
effective as anticonvulsant in a variety of experi-
mental models of epilepsy and in epileptic patients.
Pharmacological intervention along these lines may
be also beneficial in other CNS disorders and mal-
functions such as Parkinsonís disease, Huntingtonís
chorea, some forms of schizophrenia, chronic pain
and sleep disorders (3ñ6).
To date, four subtypes of membrane-bound
proteins transporting GABA have been identified
and, if they are cloned from murine brain cells, are
termed mGAT1, mGAT2, mGAT3, and mGAT4.
They display different physiological activities and
distribution in CNS. mGAT1 and mGAT4 are locat-
ed in CNS, while mGAT2 and mGAT3 are also
found in peripheral tissues (7, 8). 
The therapeutic potential of GAT inhibition
has been confirmed with the successful development
of the GAT1 selective drug tiagabine(1) which is
one of the most potent drugs used in the treatment of
epilepsy. Although the extensively investigated
GAT1 seems to be the most promising one, the three
latter still remain in the area of interest of current
medicinal chemistry (1). 
The present work is a part of an extended
search for new anticonvulsant agents and potential
antiepileptics in the group of derivatives of 4-
hydroxybutanamide (9ñ11). In this paper, we
describe the synthesis of substituted 4-hydroxybu-
tanamides and biological evaluation of their influ-
ence on murine GABA uptake proteins mGAT1-
mGAT4. The structure of compounds designed is
based on the 4-hydroxybutyric acid (γ-hydroxybu-
tyric acid, GHB), which is a metabolite of GABA,
and acts as an inhibitory neurotransmitter in mam-
malian CNS. In the position 2 of GHB, a 4,4-
diphenylbut-3-enylamine was introduced as a part
mimicking the biaryl moieties of known for selec-




Melting points were determined in open glass
capillaries on the B¸chi 353 melting point apparatus
and are uncorrected. Elemental analyses (C, H, N)
were carried out within 0.4% of the theoretical val-
ues and were performed on an Elementar Vario EL
III (Elementar Analysensysteme, Hanau, Germany).
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1H-NMR and 13C-NMR spectra were recorded on
Varian Mercury VX 300 MHz instrument in CDCl3
at ambient temperature using solvent signal as an
internal standard. Thin layer chromatography was
carried out on Merck silica gel pre-coated F254 plates
(0.2 mm) using chloroform/acetone (1:1, v/v), as a
developing system. The plates were visualized with
UV light or ninhidrin solution (0.3 g ninhidrin in
100 mL of n-butanol and 3 mL of acetic acid).
3-(4,4-diphenylbut-3-enylamino)dihydrofuran-
2(3H)-one (3)
A mixture of 2-amino-4-butyrolactone hydro-
bromide (3.17 g, 17.4 mmol), potassium carbonate
(12.04 g, 87.1 mmol), TBAB (0.56 g, 1.7 mmol)
and acetonitrile (30 mL) was stirred at room tem-
perature for 1.5 h. Then, the reaction mixture was
cooled and 4-bromo-1,1-diphenylbut-1-en (2) (5 g,
17.4 mmol) was added dropwise. After the reaction
was completed, the precipitate was filtered off,
washed with acetone (10 mL) and the filtrate was
concentrated in vacuum. The residue was purified
by column chromatography on silica gel using a
mixture of acetone and CH2Cl2 (9:1, v/v) giving (3)
as a yellow oil.
Yield 2.39 g (44 %). Analysis: calcd. for
C20H21NO2: C 78.15, H 6.89, N 4.56%; found: C
78.21, H 6.93, N 4.60%; Rf (acetone:CH2Cl2 1:9,
v/v) 0.67. 1H NMR (300 MHz, CDCl3, δ, ppm):
2.28ñ2.46 (m, 2H, CHCH2CH2), 2.63ñ2.88 (m, 2H,
=CHCH2), 3.33ñ3.69 (m, 2H, CH2NH), 3.72ñ3.77
(m, 1H, CHNH), 4.17ñ4.38 (m, 2H, CH2O),





ran-2(3H)-one (3) (1 eq.) and relevant benzylamine
(1.3 eq.) were refluxed in THF (5 mL) for 24 h. The
progress of the reaction was monitored by TLC.
Then, the solvent was evaporated and the residue
was purified by column chromatography on a silica
gel using a mixture of acetone and CHCl3 (1 : 1,
v/v). The resulting product was crystallized from the
mixture of ethyl acetate and n-hexane (7:3, v/v).
N-benzyl-2-(4,4-diphenylbut-3-enylamino)-4-
hydroxybutanamide (4a)
White solid, yield 0.5 g (70%). Analysis: calcd.
for C27H30N2O2: C 78.23, H 7.29, N 6.76%; found: C
78.21, H 7.32, N 6.83%. Rf (acetone:CHCl3 1:1, v/v)
0.50, m.p. 89.7ñ90.1OC. 1H NMR (300 MHz, CDCl3,
δ, ppm): 1.72ñ1.91 (m, 2H, CH2NH)), 2.22ñ2.31 (m,
2H, CH2CH2OH), 2.58ñ2.79 (m, 2H, =CHCH2), 3.22
(t, 1H, CHCO), 3.65ñ3.80 (m, 2H, CH2OH),
4.39ñ4.50 (m, 2H, NHCH2), 6.02 (t, 1H, =CHCH2),
7.14ñ7.37 (m, 15H, Ar), 7.44 (br s, 1H NHCH2).
N-(2-chlorobenzyl)-2-(4,4-diphenylbut-3-eny-
lamino)-4-hydroxybutanamide (4b)
White solid, yield 0.21 g (56 %). Analysis:
calc. for C27H29ClN2O2: C 72.23, H 6.51, N 6.24%;
found: C 72.15, H 6.52, N 6.23%. Rf (acetone:CHCl3
1:1, v/v) 0.58, m.p. 103.0 ñ 103.5OC. 1H NMR (300
MHz, CDCl3, δ, ppm): 1.74ñ1.86 (m, 2H, CH2NH),
2.27 (q, 2H, CH2CH2OH), 2.59ñ2.70 (m, 2H,
=CHCH2), 3.21 (t, 1H, CHCO), 3.70ñ3.77 (m, 2H,
CH2OH), 4.51 (d, 2H, NHCH2), 6.02 (t, 1H,




White solid, yield 0.32 g (48%). Analysis: calc.
for C27H29ClN2O2: C 72.23, H 6.51, N 6.24%; found:
C 72.25, H 6.57, N% 6.29%. Rf (acetone:CHCl3 1:1,
v/v) 0.71, m.p. 142.4ñ142.8OC. 1H NMR (300 MHz,
CDCl3, δ, ppm): 1.99 (dd, 2H, CH2NH)), 2.43 (q,
2H, CH2CH2OH)), 3.66ñ3.73 (m, 2H, =CHCH2),
4.08ñ4.16 (m, 3H, (CHCO; CH2NH)), 4.38 (d, 2H,
CH2OH), 5.77 (d, 2H, NHCH2), 6.05 (t, 1H,
=CHCH2) 7.13ñ7.46 (br s, 15H, Ar, NHCH2).
N-(4-fluorobenzyl)-2-(4,4-diphenylbut-3-eny-
lamino)-4-hydroxybutanamide (4d)
White solid, yield 0.36 g (51 %). Analysis: calc.
for C27H29FN2O2: C 74.97, H 6.76, N 6.48%; found:
C 75.05, H 6.77, N 6.49%. Rf (acetone:CHCl3 1:1,
Figure 1. Structure of tiagabine and SKF 89976 A 
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v/v) 0.70, m.p. 129.1ñ130.1OC. 1H NMR (300 MHz,
CDCl3, δ, ppm): 1.79 (s, 2H, CH2NH), 2.22ñ2.29 (q,
2H, CH2CH2OH), 2.59ñ2.73 (m, 2H, =CHCH2), 3.21
(t, 1H, CHCO), 3.70ñ3.81 (m, 2H, (CH2OH), 4.38
(d, 2H, NHCH2), 6.02 (t, 1H, =CHCH2), 6.94ñ7.37
(m, 14H, Ar), 7.47 (br s., 1H NHCH2).
N-(4-methylbenzyl)-2-(4,4-diphenylbut-3-enyl-
amino)-4-hydroxybutanamide (4e)
White solid, yield 0.10 g (14%). Analysis: calc.
for C28H32N2O2: C 78.43, H 7.51, N 6.54%; found: C
78.35, H 7.57, N 6.59%. Rf (acetone:CHCl3 1:1, v/v)
0.73, m.p. 130.0ñ131.5OC. 1H NMR (300 MHz,
CDCl3, δ, ppm): 1.26 (s, 3H, CH3), 1.83 (s, 2H,
CH2NH), 2.27 (s, 2H, CH2CH2OH ), 2.68 (s, 2H,
=CHCH2), 3.20 (t, 1H, CHCO), 3.73 (s, 2H,
CH2OH), 4.40 (d, 2H, NHCH2), 6.02 (t, 1H,





[3H] GABA uptake assays with GAT1-4 were
performed as previously described (12). Binding
assays for mGAT1 based on NO 711 (1-[2-
{[(diphenylmethylene)imino]oxy}ethyl]-1,2,5,6-
tetrahydro-3-pyridinecarboxylic acid) as native
marker were performed as described earlier (13).
NO 711 was analyzed by LC-MS/MS using an API
3200 triple quadrupole mass spectrometer according
to the method described previously (14). 
RESULTS AND DISCUSSION
Chemistry
The herein presented compounds (4añe) were
obtained by a simple three stage reaction pathway.
Firstly, 4-bromo-1,1-diphenylbut-1-en (2) was syn-
Scheme 1. Synthesis of 2-substituted 4-hydroxybutanamides 4añe.
Table 1. Results of [3H]GABA uptake and NO711 MS-binding assays.
Compound mGAT1 uptakea mGAT2 uptakea mGAT3 uptakea mGAT4 uptakea 
GAT1
NO711 bindingb
4a 4.15 ± 0.12 4.44 ± 0.05 4.60 ± 0.11 4.72 ± 0.10 4.47 ± 0.05
4b 4.54 ± 0.13 4.69 ± 0.03 4.73 ± 0.04 4.96 ± 0.02 47%
4c 4.43 ± 0.10 4.54 ± 0.10 4.80 ± 0.07 67% 92%
4d 4.43 ± 0.05 4.32 ± 0.14 4.49 ± 0.04 4.89 ± 0.13 75%
4e 74% 54% 46% 97% 86%
Tiagabine[14] 6.88 ± 0.12 52% 64% 73% ñ 
a % of remaining GABA uptake at 100 mM concentration of tested compound (the means; n = 3) or pIC50 (the mean ± SEM; n = 3). b %
of NO711 bound to GAT1 at 100 mM concentration of tested compound (the means; n = 3) or pKi (the mean ± SEM; n = 3).
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thesized by solvolysis of cyclopropyldiphenyl-
carbinol (1) in concentrated hydrobromic acid (15).
Then, the 3-(4,4-diphenylbut-3-enylamino)dihydro-
furan-2(3H)-one (3) was obtained by N-alkylation of
2-amino-4-butyrolactone with compound 2. The
reaction was carried out in acetonitrile in the pres-
ence of anhydrous K2CO3 at room temperature for
24 h. Finally, the aminolysis of the lactone (3) by
relevant substituted benzylamines resulted in
amides of 2-substituted-4-hydroxybutanoic acid
(4añe). The aminolysis was performed by heating
substrates in THF for 24 h. The course of the per-
formed reactions is presented in Scheme 1.
Biological evaluation
Inhibitory potency of the compounds 4añe was
tested at four murine GABA transporter subtypes
mGAT1ñmGAT4. The study was performed as the
[3H]GABA uptake assay based on stably transfected
HEK cells, according to the procedure recently
described (12). The affinity to mGAT1 was deter-
mined by MS-binding assay with NO711 as a non-
labeled marker (13, 14). The compounds were con-
sidered active, when at a concentration of 100 mM
reduced GABA uptake or NO711 binding at least by
50%. For the active compounds, pIC50 values were
assessed. Based on results obtained, compounds
4añd showed inhibitory potency of mGAT1ñ4 (Tab.
1).
The newly synthesized compounds 4a-d were
found to be GABA uptake inhibitors, while com-
pounds 4e was not active in those tests. It is also
worth to know that compounds 4a, 4b and 4d were
also slightly selective towards GAT4. The highest
potency towards GAT4 (pIC50 4.96) was observed
for compound 4b, which contains a chlorine atom at
the ortho- position of benzyl fragment of the mole-
cule. In comparison to unsubstituted compound 4a,
introduction of halide atom in the ortho- (4b) or
para- (4c, 4d) position of benzyl fragment resulted
in increasing inhibitory activity of the compounds
obtained. Among compounds tested only compound
4a displaced NO 711 from binding with pKi = 4.47.
CONCLUSION
In summary, various substituted N-benzyl-2-
(4,4-diphenylbut-3-enylamino)-4-hydroxybu-
tanamides (4a-4e) have been synthesized. All com-
pounds have been evaluated regarding their inhibito-
ry potency and subtype selectivity at the four murine
GABA transporters subtypes mGAT1-mGAT4. The
compounds obtained displayed activity at the
GABA transport proteins. Although no general
dependency from substituent in benzyl fragment of
molecules could be determined, these compounds
might represent a good starting point for the devel-
opment of new class of GABA-uptake inhibitors.
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